from the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001043), the UK Medical Research Council (FC001043) and the Wellcome Trust (FC001043)
Cell 184 , 26962714.e2625 (2021)
Much of the enthusiasm for GHK-Cu rests on laboratory studies, animal wound models and small human trials , not large randomized controlled trials of cosmetic anti-aging outcomes
Typical dosing protocols used in research settings have varied considerably, with reported ranges from 5-10 mg administered subcutaneously for periods of 10-20 days, often followed by several months without treatment

[26] [27] [28] Hypoglycemia, arginine, [29] pramipexole, [30] ornithine, lysine, tryptophan, -Aminobutyric acid and propranolol by inhibiting somatostatin release [25] Deep sleep [31] Glucagon Sodium oxybate or -Hydroxybutyric acid Niacin as nicotinic acid (vitamin B 3 ) [32] Fasting [33] Insulin [34] Vigorous exercise [35] Inhibitors of GH secretion include: GHIH ( somatostatin ) from the periventricular nucleus [36] circulating concentrations of GH and IGF-1 (negative feedback on the pituitary and hypothalamus) [3] Hyperglycemia [25] Glucocorticoids [37] Dihydrotestosterone Phenothiazines In addition to control by endogenous and stimulus processes, a number of foreign compounds (xenobiotics such as drugs and endocrine disruptors) are known to influence GH secretion and function